TuisIONS • NASDAQ
add
Ionis Pharmaceuticals Inc
Vorige sluiting
$29,10
Dagwisseling
$28,79 - $29,78
Jaarwisseling
$23,95 - $52,34
Markkapitalisasie
4,70 mjd USD
Gemiddelde volume
1,76 m
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
NASDAQ
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Des. 2024info | J/J-verandering |
|---|---|---|
Inkomste | 226,58 m | -30,18% |
Bedryfskoste | 88,08 m | 72,67% |
Netto inkomste | -104,35 m | -1 026,51% |
Netto winsgrens | -46,05 | -1 515,79% |
Wins per aandeel | -0,43 | -464,44% |
EBITDA | -108,12 m | -733,19% |
Effektiewe belastingkoers | 2,51% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Des. 2024info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 2,30 mjd | -1,48% |
Totale bates | 3,00 mjd | 0,45% |
Totale aanspreeklikheid | 2,42 mjd | -7,22% |
Totale ekwiteit | 588,35 m | — |
Uitstaande aandele | 158,96 m | — |
Prys om te bespreek | 7,80 | — |
Opbrengs op bates | -9,11% | — |
Opbrengs op kapitaal | -10,65% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Des. 2024info | J/J-verandering |
|---|---|---|
Netto inkomste | -104,35 m | -1 026,51% |
Kontant van bedrywe | -116,14 m | -453,38% |
Kontant van beleggings | 68,21 m | 355,36% |
Kontant van finansiering | -44,12 m | -208,33% |
Netto kontantverandering | -92,53 m | -296,01% |
Beskikbare kontantvloei | -113,03 m | -268,37% |
Meer oor
Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California, that specializes in discovering and developing RNA-targeted therapeutics. The company has three commercially approved medicines: Spinraza, Tegsedi, and Waylivra, and has four drugs in pivotal studies: tominersen for Huntington's disease, tofersen for SOD1-ALS, AKCEA-APO-LRx for cardiovascular disease, and AKCEA-TTR-LRx for all forms of TTR amyloidosis.
The company was named Isis Pharmaceuticals until December 2015. Wikipedia
Gestig
1989
Hoofkwartier
Webwerf
Werknemers
1 069
